It was shown that OCT1-expressing cell lines derived from lymphoma and OCT1-transfected CHO cells exhibited higher sensitivity to the cytotoxic effects of irinotecan and paclitaxel than cells that did not express OCT1 [94]. The gene discussed is SLC22A1; the disease is lymphoma.